Should China Be Considered For Clinical Trials?

June 18, 2019 8:00 AM - 10:00 AM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

Offshoring of clinical trials can provide many benefits to pharma companies interested in reducing preapproval expenditures. However, many factors such as national infrastructure, patient pool, quality of data, and clinical expertise must be considered before selecting a country outside the US for each particular trial. China is making progress in attracting clinical trials due to its faster setup times, lower cost and improved quality data. Recent regulatory reforms of the clinical trial process have shortened the timeline to approval and have led to increased investment in China. Offshoring clinical trials to China can be an effective strategy to reduce cost and cycle time of drug development. China also has significant market potential and strong research capacity that can provide long term benefits to pharmaceutical and biotech companies. We will discuss the opportunity but also the challenges and how to minimize the associated risks.

Key questions our panel will address: